Brief: Oramed Subsidiary Oravax Medical And Genomma Lab Internacional Announce Joint Venture To Develop And Commercialize Oral COVID-19 Vaccine In Mexico
18/11/2021 12:44
Nov 18 (Reuters) - Genomma Lab Internacional SAB de CV
LABB.MX :
* ORAMED SUBSIDIARY ORAVAX MEDICAL AND GENOMMA LAB
INTERNACIONAL
ANNOUNCE JOINT VENTURE TO DEVELOP AND COMMERCIALIZE ORAL
COVID-19 VACCINE IN MEXICO AND DRIVE BUSINESS DEVELOPMENT IN
LATIN AMERICA
* ORAMED PHARMACEUTICALS INC - ANNOUNCED A 50/50 JOINT
VENTURE
BETWEEN GENOMMA LAB AND ORAMED'S SUBSIDIARY ORAVAX MEDICAL INC
Source text for Eikon: ID:nPn9fNnjva
Further company coverage: LABB.MX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results